Biotech’s latest plot twist has Wall Street grinning: a Big Pharma icon betting billions on psychedelics, a transplant diagnostics player finally getting its Medicare script approved, and a quietly ambitious drug-delivery innovator upgrading its cast of characters for the next act.
Lilly’s…